The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

There's widespread confusion and fear among scientists and doctors on the sprawling National Institutes of Health campus and ...

While the threat of tariffs raises the specter of drug shortages and rising prices, patient advocate Dr. Bill Hennessy ...

Sen. Bill Cassidy, whose “yes” vote advanced Kennedy’s nomination as health secretary, said Kennedy promised to maintain a ...

As part of the de-wokeification process, Trump’s administration has eviscerated more than 8,000 pages of materials just since ...

The U.S. Senate Finance Committee could vote as soon as Tuesday on Robert F. Kennedy Jr.’s controversial nomination to be ...

I worked closely with NCI’s Investigational Drug Branch (IDB) from 1990-2016, including as a principal investigator of one of ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.

Hopkins researchers help secure full FDA approval to treat immunocompromised COVID-19 patients—paving the way to explore ...